Abstract
Precision medicine (PM) is increasingly being described as a paradigm shift in our understanding of medicine and as the future of clinical practice since it promises the possibility to individualize the healthcare in order to achieve optimal treatment with minimal adversity. Advances in the fields of omics, next generation sequencing (NGS), artificial intelligence (AI) and big data have strongly augmented this approach and rendered it clinically feasible instead of relying on the conventional nosology and broad symptomatic presentations. Oncology has, so far, benefited the most from this strategy as evidenced by genetic markers and biomarkers-guided pharmacotherapeutics that have found their way into guidelines and protocols. Meanwhile, nucleoside analogues, that represent a fundamental class in solid and hematologic tumors treatment, are still far from being adequately included in this trending modality due to lacking sufficient valid clinical proofs. The well-studied drugs’ paths, however, pave the way towards this goal, hoping to transfer the hype into bedside reality.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ALK:
-
Anaplastic lymphoma kinase
- ASO:
-
Antisense oligonucleotide
- BC:
-
Bladder cancer
- COPD:
-
Chronic obstructive pulmonary disease
- CCD:
-
Complex chronic diseases
- CDA:
-
Cytidine deaminase
- dCK:
-
Deoxycytidine kinase
- EGFR:
-
Epidermal growth factor receptor
- HER-2:
-
Human epidermal growth factor receptor 2
- hENT:
-
Human equilibrative nucleoside transporter
- mAb:
-
Monoclonal antibodies
- NA:
-
Nucleoside analogue
- PRECeDI:
-
Personalized prevention of chronic diseases
- PK:
-
Pharmacokinetics
- PM:
-
Precision medicine
- siRNA:
-
Small interfering RNA
- TDM:
-
Therapeutic drug monitoring
- TKI:
-
Tyrosine kinase inhibitors
References
Abbaspour A, Dehghani M, Setayesh M et al (2023) Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients. Cancer Chemother Pharmacol. https://doi.org/10.1007/s00280-023-04579-8
Aldeen Majeed AA, Salih Sahib A, Shakir Mahmood H et al (2023) Association of cytidine deaminase polymorphism with capecitabine effectiveness in breast cancer patients. Asian Pacific J Cancer Prev 24:4219–4225. https://doi.org/10.31557/APJCP.2023.24.12.4219
Aramini B, Masciale V, Banchelli F et al (2020) Precision medicine in lung cancer: challenges and opportunities in diagnostic and therapeutic purposes. In: Park HS (ed) Lung Cancer. IntechOpen, Rijeka
Bernell S, Howard SW (2016) Use your words carefully: What is a chronic disease? Front Public Heal 4:159. https://doi.org/10.3389/fpubh.2016.00159
Bilkey GA, Burns BL, Coles EP et al (2019) Optimizing precision medicine for public health. Front Public Heal 7:42. https://doi.org/10.3389/fpubh.2019.00042
Blackstone EH (2019) Precision medicine versus evidence-based medicine. Circulation 140:1236–1238. https://doi.org/10.1161/CIRCULATIONAHA.119.043014
Boccia S, Pastorino R, Ricciardi W et al (2019) How to integrate personalized medicine into prevention? Recommendations from the personalized prevention of chronic diseases (PRECeDI) consortium. Public Health Genom 22:208–214. https://doi.org/10.1159/000504652
Chung KF (2018) Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med 24:4–10. https://doi.org/10.1097/MCP.0000000000000434
Ciccolini J, Serdjebi C, Le Thi ThuH et al (2016) Nucleoside analogs: ready to enter the era of precision medicine? Expert Opin Drug Metab Toxicol 12:865–877. https://doi.org/10.1080/17425255.2016.1192128
Conti M, Matulli Cavedagna T, Ramazzotti E et al (2018) Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS. Clin Mass Spectrom 7:6–17. https://doi.org/10.1016/j.clinms.2017.12.002
Crooke ST, Baker BF, Crooke RM, Liang X (2021) Antisense technology: an overview and prospectus. Nat Rev Drug Discov 20:427–453. https://doi.org/10.1038/s41573-021-00162-z
Derissen EJB, Beijnen JH (2020) Intracellular pharmacokinetics of pyrimidine analogues used in oncology and the correlation with drug action. Clin Pharmacokinet 59:1521–1550. https://doi.org/10.1007/s40262-020-00934-7
Ewald B, Sampath D, Plunkett W (2008) Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 27:6522–6537. https://doi.org/10.1038/onc.2008.316
Fanciullino R, Farnault L, Donnette M et al (2018) CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine. Blood Adv 2:462–469. https://doi.org/10.1182/bloodadvances.2017014126
Gabor KM, Schermann G, Lautner-Csorba O et al (2015) Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 62:622–628. https://doi.org/10.1002/pbc.25379
Galmarini CM, Mackey JR, Dumontet C (2002) Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3:415–424. https://doi.org/10.1016/s1470-2045(02)00788-x
García-González X, Cortejoso L, García MI, García-Alfonso P, Robles L, Grávalos C, González-Haba E, Marta P, Sanjurjo M, López-Fernández LA (2015) Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer. Oncotarget 6(8):6422–6430. https://doi.org/10.18632/oncotarget.3289
Gómez-Carrillo A, Paquin V, Dumas G, Kirmayer LJ (2023) Restoring the missing person to personalized medicine and precision psychiatry. Front Neurosci 17:1041433. https://doi.org/10.3389/fnins.2023.1041433
Hahn VS, Petucci C, Kim M-S et al (2023) Myocardial metabolomics of human heart failure with preserved ejection fraction. Circulation 147:1147–1161. https://doi.org/10.1161/CIRCULATIONAHA.122.061846
Halpin DMG (2022) Precision medicine in chronic obstructive pulmonary disease. Chin Med J (engl) 135:1156–1162. https://doi.org/10.1097/CM9.0000000000002042
Hayes DF, Schott AF (2015) Personalized medicine: genomics trials in oncology. Trans Am Clin Climatol Assoc 126:133–143
Holman HR (2020) The relation of the chronic disease epidemic to the health care crisis. ACR Open Rheumatol 2:167–173. https://doi.org/10.1002/acr2.11114
Huang S, Bian Y, Huang C, Miao L (2022) Is monitoring of the intracellular active metabolite levels of nucleobase and nucleoside analogs ready for precision medicine applications? Eur J Drug Metab Pharmacokinet 47:761–775. https://doi.org/10.1007/s13318-022-00786-5
Jordheim LP, Durantel D, Zoulim F, Dumontet C (2013) Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 12:447–464. https://doi.org/10.1038/nrd4010
Jørgensen JT (2008) From blockbuster medicine to personalized medicine. Per Med 5:55–63. https://doi.org/10.2217/17410541.5.1.55
Joshi E, Nanayakkara B, Barnes DJ, Troy LK (2020) Precision medicine in lung cancer. EMJ Oncol. https://doi.org/10.33590/emjoncol/19-00145
Kamel S, Yehia H, Neubauer P, Wagner A (2018) Enzymatic synthesis of nucleoside analogues by nucleoside phosphorylases. In: Fernández-Lucas J, Camarasa-Rius M (eds) Enzymatic and chemical synthesis of nucleic acid derivatives. Wiley, pp 1–28
König IR, Fuchs O, Hansen G et al (2017) What is precision medicine? Eur Respir J 50:1700391. https://doi.org/10.1183/13993003.00391-2017
Lamichhane P, Agrawal A (2023) Precision medicine and implications in medical education. Ann Med Surg 85:1342–1345. https://doi.org/10.1097/MS9.0000000000000298
Lee J, Aziz H, Liu L et al (2011) β1-adrenergic receptor polymorphisms and response to β-blockade in the African–American study of kidney disease and hypertension (AASK). Am J Hypertens 24:694–700. https://doi.org/10.1038/ajh.2011.39
Leung JM, Obeidat M, Sadatsafavi M, Sin DD (2019) Introduction to precision medicine in COPD. Eur Respir J 53:1802460. https://doi.org/10.1183/13993003.02460-2018
Manchia M, Pisanu C, Squassina A, Carpiniello B (2020) Challenges and future prospects of precision medicine in psychiatry. Pharmgenomics Pers Med 13:127–140. https://doi.org/10.2147/PGPM.S198225
Mathur S, Sutton J (2017) Personalized medicine could transform healthcare (review). Biomed Rep 7:3–5. https://doi.org/10.3892/br.2017.922
McCormack M, Alfirevic A, Bourgeois S et al (2011) HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364:1134–1143. https://doi.org/10.1056/NEJMoa1013297
Megías-Vericat JE, Martínez-Cuadrón D, Solana-Altabella A et al (2022) Systematic review of pharmacogenetics of ABC and SLC transporter genes in acute myeloid leukemia. Pharmaceutics 14:878. https://doi.org/10.3390/pharmaceutics14040878
Michelotti A, de Scordilli M, Bertoli E et al (2022) NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease. Int J Mol Sci 23:6748. https://doi.org/10.3390/ijms23126748
Muharremi G, Meçani R, Muka T (2024) The buzz surrounding precision medicine: the imperative of incorporating it into evidence-based medical practice. J Pers Med 14:53. https://doi.org/10.3390/jpm14010053
Naithani N, Atal AT, Tilak TVSVGK et al (2021) Precision medicine: uses and challenges. Med J Armed Forces India 77:258–265. https://doi.org/10.1016/j.mjafi.2021.06.020
Oberemok VV, Laikova KV, Repetskaya AI et al (2018) A half-century history of applications of antisense oligonucleotides in medicine, agriculture and forestry: we should continue the journey. Molecules 23:1302. https://doi.org/10.3390/molecules23061302
Pastorino R, Loreti C, Giovannini S et al (2021) Challenges of prevention for a sustainable personalized medicine. J Pers Med 11:311. https://doi.org/10.3390/jpm11040311
Phillips ML, Chase HW, Sheline YI et al (2015) Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. Am J Psychiatry 172:124–138. https://doi.org/10.1176/appi.ajp.2014.14010076
Quemener AM, Bachelot L, Forestier A et al (2020) The powerful world of antisense oligonucleotides: from bench to bedside. Wires RNA 11:e1594. https://doi.org/10.1002/wrna.1594
Rabie AM (2022) Efficacious preclinical repurposing of the nucleoside analogue didanosine against COVID-19 polymerase and exonuclease. ACS Omega 7:21385–21396. https://doi.org/10.1021/acsomega.1c07095
Rizzo A, Mollica V, Cimadamore A, Santoni M, Scarpelli M, Schiavina R, Cheng L, Lopez-Beltran A, Brunocilla E, Montironi R, Massari F (2021) TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review. Transl Androl Urol 10(3):1541–1552. https://doi.org/10.21037/tau-20-1109
Rudd SG (2023) Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities. Cancer Chemother Pharmacol 92:241–251. https://doi.org/10.1007/s00280-023-04562-3
Ryk C, Koskela LR, Thiel T et al (2015) Outcome after BCG treatment for urinary bladder cancer may be influenced by polymorphisms in the NOS2 and NOS3 genes. Redox Biol 6:272–277. https://doi.org/10.1016/j.redox.2015.08.008
Savić D, Stanković T, Lavrnja I et al (2015) Purine nucleoside analogs in the therapy of cancer and neuroinflammation. Mol Inhib Target Ther 1:3–14. https://doi.org/10.1515/motth-2015-0002
Seley-Radtke KL, Yates MK (2018) The evolution of nucleoside analogue antivirals: a review for chemists and non-chemists. Part 1: early structural modifications to the nucleoside scaffold. Antiviral Res 154:66–86. https://doi.org/10.1016/j.antiviral.2018.04.004
Sethi Y, Patel N, Kaka N et al (2023) Precision medicine and the future of cardiovascular diseases: a clinically oriented comprehensive review. J Clin Med 12:1799. https://doi.org/10.3390/jcm12051799
Sidhaye VK, Nishida K, Martinez FJ (2018) Precision medicine in COPD: where are we and where do we need to go? Eur Respir Rev 27:180022. https://doi.org/10.1183/16000617.0022-2018
Su H, Jiang H, Tao T et al (2019) Hope and challenge: Precision medicine in bladder cancer. Cancer Med 8:1806–1816. https://doi.org/10.1002/cam4.1979
Subhan MA, Parveen F, Shah H et al (2023) Recent advances with precision medicine treatment for breast cancer including triple-negative sub-type. Cancers (basel) 15:2204. https://doi.org/10.3390/cancers15082204
Taliun D, Harris DN, Kessler MD et al (2021) Sequencing of 53,831 diverse genomes from the NHLBI TOPMed program. Nature 590:290–299. https://doi.org/10.1038/s41586-021-03205-y
Thiele I, Yehia H, Krausch N et al (2023) Production of modified nucleosides in a continuous enzyme membrane reactor. Int J Mol Sci 24:6081. https://doi.org/10.3390/ijms24076081
Thomson JM, Lamont IL (2019) Nucleoside analogues as antibacterial agents. Front Microbiol 10:952. https://doi.org/10.3389/fmicb.2019.00952
Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N (2018) Nucleobase and nucleoside analogues: Resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism. Cancers (basel) 10:240. https://doi.org/10.3390/cancers10070240
Visvikis-Siest S, Theodoridou D, Kontoe MS et al (2020) Milestones in personalized medicine: From the ancient time to nowadays—the provocation of COVID-19. Front Genet 11:569175. https://doi.org/10.3389/fgene.2020.569175
Whitcomb DC (2019) Primer on precision medicine for complex chronic disorders. Clin Transl Gastroenterol 10(7):e00067. https://doi.org/10.14309/ctg.0000000000000067
Xi Z, Zhou Y, Zhao Y et al (2020) Ticagrelor versus clopidogrel in patients with two CYP2C19 loss-of-function alleles undergoing percutaneous coronary intervention. Cardiovasc Drugs Ther 34:179–188. https://doi.org/10.1007/s10557-020-06956-4
Yang S-R, Schultheis AM, Yu H et al (2022) Precision medicine in non-small cell lung cancer: current applications and future directions. Semin Cancer Biol 84:184–198. https://doi.org/10.1016/j.semcancer.2020.07.009
Yehia H, Kamel S, Paulick K et al (2017) Substrate spectra of nucleoside phosphorylases and their potential in the production of pharmaceutically active compounds. Curr Pharm Des 23:6913–6935. https://doi.org/10.2174/1381612823666171024155811
Yssel AEJ, Vanderleyden J, Steenackers HP (2017) Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors. J Antimicrob Chemother 72:2156–2170. https://doi.org/10.1093/jac/dkx151
Zandi K, Amblard F, Musall K et al (2020) Repurposing nucleoside analogs for human coronaviruses. Antimicrob Agents Chemother 65:e01652-e1720. https://doi.org/10.1128/AAC.01652-20
Zhang L, Chen M, Feng B et al (2015) Imatinib-based therapy in adult Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report and literature review. Oncol Lett 10:2051–2054. https://doi.org/10.3892/ol.2015.3539
Funding
This work received no grants from any funding agency in the public, commercial, or not-for-profit sectors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical statement
This article does not contain any studies involving animals performed by any of the authors. This article does not contain any studies involving human participants performed by any of the authors.
Conflict of interest
Heba Yehia has no conflicts of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yehia, H. Precision medicine engaging nucleoside analogues: New advances to a conventional arsenal. ADV TRADIT MED (ADTM) (2024). https://doi.org/10.1007/s13596-024-00747-0
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13596-024-00747-0